


**CUMULATIVE INDEX**

**VOLUME 8, NUMBERS 1-3**

**MARCH-SEPTEMBER, 1965**



## CUMULATIVE INDEX

**Boldface type** shows inclusive page numbers of articles or extensive discussion.

- A**bstortion  
habitual, 92-93  
uterine deformity as cause, 50, 52  
Acromegaly, effect on fertility, 74  
Adenohypophysis. *See* Pituitary, anterior  
Adenomyosis, estrogen excretion in, 559-560  
Adolescence  
adults, identification with, in, 149  
attitudes towards, 150-158  
of adolescent, **150-153**  
of parents, **153-155**  
of physician, **155-158**  
"body image," development of, 147  
conflicts, oedipal, 148-149  
disillusionment, process of, 149-150  
dysmenorrhea, response to, 152-153, 228, 230, 231-232  
physiology, changes in, **147-150**  
response to, 151  
SLE as cause, 277, 315  
Adrenalcortical hormones, 526-527  
Aldosterone  
in nonpregnant female, 526-527, 544  
in pregnancy, 544-545  
and relation to sodium ingestion, 544  
Amenorrhea  
bioassays, use of, in determining cause of, 106-107  
without demonstrable disease, 101  
from failure of gonadotropin secretion, 523  
"hypothalamic," 77, 102-103  
"mother-in-law," 102  
persistent lactation, 74, 75-77  
*See also* Chiari-Frommel syndrome  
primary, with anovulation, 60-62  
clinical types of, 61-62  
secondary, due to adrenal disorders, 83  
temporary, 102  
and vesicocervical fistula, 478  
"war," 102  
Anastomosis  
to intact bowel, 730, 733-734  
ureterocutaneous, **726-730**  
bilateral side-to-side, 729-730, 731, 732  
clinical evaluation, 726-727  
complications of, 727  
flank ureterostomy, 728-729  
operative techniques, **727-730**  
radiation effect on, 734  
ureterointestinal, 730, **733-754**  
clinical evaluation, 730, **733-736**  
complications of, 733-734  
to intact bowel, 730, 733-734  
to large bowel above colostomy, 734  
operative technique, **737-740**  
operative techniques, **736-754**  
pyeloileal cutaneous, 735-736  
operative technique, 746, **748-754**  
wet colostomy, 734  
operative technique, **737-740**  
Anemia  
in rheumatoid arthritis, 288  
in SLE, 317, 318  
Anencephaly, decreased estriol excretion in, 560  
Anovulation and primary amenorrhea, 60-62  
Anticoagulant therapy, after pelvic surgery, 637  
Anuria  
postoperative, 414, 417-421  
management of, **418-421**  
decompression, 420-421  
by intubated ureterostomy, 421  
by nephrostomy, 421  
by pyelostomy, 421  
PSP test, 419  
removal of ligature, 420  
Artificial insemination  
donor, 135  
homologous, 27-29, 135  
indications for, 27-28, 135  
Aspermia, 121  
Autoimmunity, 94-95, 272-273  
mechanisms of, 272-273  
and rheumatoid arthritis, 274-275  
**B**ladder  
bisection of, 484-485  
flap, 435-436, 437-438  
injuries to, 376, 377, 378  
reimplantation of ureter into, 435-436  
vesicovaginal fistula, 485, **486-492**

Pages 1-248, March issue; pages 249-504, June issue; pages 505-800, September issue.

## Bowel

- preoperative preparation, 632
- postoperative care, 638-639

## Cancer

- cervical, 392-395, 616-612
  - paravaginal hysterectomy for, 616
  - with lymph node dissection, 616
  - with X-ray therapy to nodes, 616
- radiation therapy for, 616
  - combined with surgery, 621
  - comparison with surgical therapy, 617-619
  - complications, 393, 394, 617-618
  - radioresistant, 621-623
  - determination of inoperability, 622-623
- radiosensitivity of tumors, 619
- radiation response, 620
- sensitization response, 619-620
- recurrent, 622, 705
- surgical treatment of, 616, 617
  - See also specific operations*
  - abdominal vs. vaginal approach, 676-677
  - compared with radiation therapy, 617-619
  - complications, 617, 618, 619
  - with radiation, 621
  - Schauta-Amreich operation for, 676-703
  - total pelvic evisceration, 705-723
  - Wertheim operation for, 616
- endometrial, 623-624
- genital tract, carcinoma in situ, 757-769
  - classification, 757
  - incidence after cervical conization, 757-760
  - incidence after hysterectomy, 760
  - multicentric foci of origin, 761-764
  - recurrent, 764-766
    - diagnosis, 765-766
    - surgical technique, 766-768
  - residual disease, 757-761
  - radiation treatment of, 760-761
  - surgical treatment of, 761
- ovarian, 386
- pelvic
  - radical surgery for, 611-625
- of the ureter, 392-395
- urethral, 365-366
- vaginal, 614-616
  - radiation therapy for, 615, 616
  - radical surgery for, 615, 616

- ratio of, to cervical malignancy, 614
- vulvar, 612-614
  - electrocoagulation, 614
  - irradiation of nodes, 614
  - radical surgery for, 612-614
  - mortality, 613-614

Carcinoma. *See* Cancer

## Caruncle of urethra, 363-364

## Cervix

- anatomy and physiology of, 15-16
- cancer of, 392-395, 616-623
- carcinoma in situ following conization, 757-760
- endocervical gland, 16, 17
- mucus
  - arborization of, 18, 22-23
  - bacteriology of, 23
  - biochemistry and infertility, 19
  - characteristics, 16-19, 22
  - electrocauterization, 20, 23
  - evaluation of, 22-23
  - postcoital test for, 23-25
    - See also* Postcoital test
  - spermatozoa compatibility, in vitro test of, 25
- pH, 23
- spinnbarkeit, 16, 17, 22
- viscosity, 16

## Chiari-Frommel syndrome, 74, 75-77

Chromatography, gas liquid

- for measuring urinary estriol excretion, 517-518

## Collagen, 334

- diseases, 273-277
  - characteristics of, 273-274
  - in pregnancy, 276-277
- See also specific collagen diseases*

## Colostomy

- postoperative care, 639
- wet, 734
  - operative technique, 737-740

Compound F. *See* Cortisol

## Conization, cervical

- incidence of carcinoma following, 757-670

## Contraception

- criteria for, 96
- immunologic aspects, 96-97
  - See also* Infertility, immunologic causes of

## Corticosterone, 543

## Cortisol, 526, 543-544

- in nonpregnant state, 543
- in pregnancy, 543-544

- Cortisone, 543  
 Cyst, suburethral, 366-367
- Delivery**  
 effect of polyarteritis nodosa, 331  
 effect of rheumatoid arthritis, 295  
 of sclerodermic patient, 283-284  
 unexplained premature, and estriol levels in, 552, 553
- Depression, in gynecologic patient, 236-239
- Dermatomyositis, 304-306  
 age incidence, 304  
 clinical picture, 304-305  
 laboratory findings, 305  
 pathology, 304  
 and pregnancy, 305-306  
 prognosis, 305  
 and Raynaud's phenomenon, 304  
 sex incidence, 304  
 treatment, 306  
   adrenal steroids in, 306
- Diabetes and pregnancy  
 urinary estriol excretion tests, 518
- Doctor-patient relationship  
 in gynecology, 174-183, 189-190  
 with adolescent, 155-158  
 dangers involved in, 184-195  
   psychopathology, 184-190  
   determinants of, 176-182  
   problem patient, 190-193
- Dribbling. *See* Urinary incontinence, dribbling
- Dysmenorrhea  
 adolescent response to, 152-153  
 periodic, 235  
 psychological factors in, 222-232
- Ehlers-Danlos syndrome**, 337
- Electrocauterization, effect on cervical mucus, 20, 23
- Electrocoagulation therapy for urethrovaginal fistulas, 424  
 for vesicovaginal fistulas, 465-482
- Electrolytes, postoperative replacement, 638
- Endocrine activity  
 in nonpregnant female, 521-527  
   of placenta, 580-597  
   of pregnancy, 528-547
- Endometriosis, 55-56, 66-67  
 diagnosis of, 55-57  
 distortion of anatomic relations of pelvis, 377  
 and sterility, incidence of, 55, 66-67  
   treatment of, 56, 67  
   of ureter, 386
- Endometrium, cancer of, 623-624
- Enovid, for suppression of lactation, 517
- Enzymes, oxytocin inactivating, 530
- Epispadias, 357
- Erythroblastosis  
 increase in HCG level, 533  
 placenta in, 557  
 urinary estriol levels in, 556-557
- Estriol**  
 in abnormal pregnancy, 550, 552-560  
   adenomyosis, 559-560  
   anencephaly, 560  
   erythroblastosis, 556-557  
   in fetal death, 560  
   in hydatidiform mole, 560  
   placental insufficiency in, 560  
   in pregnant diabetic, 558-559  
   in pyelonephritis, 555-556  
   in spontaneous premature membrane rupture, 552-554  
 in normal pregnancy, 550-552  
 in toxemia of pregnancy, 554-555  
   in twin births, 558  
   in unexplained premature delivery, 552, 553
- Estrogen(s)**  
 in nonpregnant female, 523-525  
   in adolescent, 539  
   adrenal, 523  
   bioassay of, 524-525  
   chemical measurement of, 524  
   effects of, 525  
   estradiol-17 $\beta$ , 523  
   estriol, 523  
   estrone, 523  
   in menstrual cycle, 539  
   ovarian, 523-525  
 in pregnant female, 539-541  
   combined with progestational agents, 567  
   estradiol-17 $\beta$ , 540
- Fallopian tube. See** Tubes, fallopian
- Fetal death  
 artificially induced and urinary excretion of hormones, 581  
 associated with missed abortion, 518-519  
 indications of impending, 518  
 urinary estriol levels in, 560
- Fetomaternal exchange of steroids, 518-519

## Fetus

- death of. *See* Fetal death
- effect of drug therapy on, 295, 300
- effect of SLE on, 312, 313
- estriol excretion and size of, 518, 541
- source of growth hormone in, 535-538

## Fibroids, 386

## Fistulas

- obstetric, 376, **472-482**, 483
- postcesarean, **472-482**
  - operative management, 472-473
  - postoperative management, 473
  - preoperative management, 472
- postoperative, 376, 392, 393-394
- rectovaginal, following radical pelvic surgery, 780
- urethrovaginal, 374, 391, 392, 415
  - differentiation of vesicovaginal, 417, 418
  - treatment of, **421-440**
    - conservative, 422, **423-428**
      - cystoscopy with insertion of catheter, 424, 427, 428
      - electrocoagulation, 424
      - watchful waiting, 422, 423-424, 425, 426
    - restoration of ureteral continuity, **434-438**
      - closure of fistula with suture, 434-435
      - by downward displacement of kidney and ureter, 436
      - reimplantation of ureter into bladder, 435-436
        - by bladder flap, 435-436, 437-438
      - by ureteroneocystostomy, 435, 776, 777
    - suppression of further secretion of urine, 429-432, 433
    - intentional ligation of ureter, 432
      - by nephrectomy, 429-432, 433
  - ureteroplasty, 439-440
    - transureteroureteral anastomosis, 439
    - ureteroileocystoplasty, 439-440, 776, 778
    - ureteroureteral anastomosis, 439
  - urinary diversion, 432, 434, **711-715**, **726-755**
    - use of isolated segment of ileum, 439
    - by nephrostomy, 432
    - by ureteroileostomy, 434

by ureterosigmoidostomy, 434, 730

by cutaneous ureterostomy, 432, 434, **726-730**

vesicocervical, 475, 478, 479

occurrence of symptoms, 475, 478

menouria, 478-479

urinary leakage, 478

surgical repair of, 479

vesicocervicovaginal, 473-475

case study, 475

catheterization for, 475

surgical repair, 475, 476, 477

vesicouterine, 480-482

vesicovaginal

coagulation therapy for, **465-482**

criteria for use, 466-467

results, 469, 470

technique of, 468-469

anesthesia for, 468

catheterization, 469

cystoscopic evaluation, 467-468

differentiation of ureterovaginal, 417, 418

following diverticulectomy, 374

following gynecologic surgery, 483, 484

following pelvic irradiation, 779

following total hysterectomy, 376, 465-466, 624, 706, **775-779**

analysis of cases, 466-467

prevention of, **376-382**

repair of, **776-779**

methods of repair, 492-493

multiple operations, 483-484, 485

after pelvic surgery, 483, **775-779**

site of fistula, 483

postcesarean, 472, 473

preoperative insertion of catheter, 396

principles of management, 485-486

transvesical approach to, **483-494**

postoperative care, 489

results, 489, 492

technique for, 484-485, **486-489**, 490-491

**Galactopoiesis**, 601, 604-605

Gas liquid chromatography, 517-518

Gonadotropin(s), 532-533

assay of, 91-92, 521-522

chorionic (HCG), 532-533

during pregnancy, 533

follicle-stimulating hormone (FSH), 521, 523, 531

- in reproductive process, 532
- human pituitary gonadotropin (HPG), 522
- interstitial cell-stimulating hormone (ICSH), 521, 523, 531
  - in reproductive process, 532
- luteinizing hormone (LH), 521, 531
- mechanism of secretion, 522-523
  - failure of, 523
- in nonpregnant female, 521-523
- pituitary, 532
- in postmenopausal women, 522
- production of, 521
- prolactin (luteotropin), 521
- Gonorrheal urethritis, 359-360
  - laboratory diagnosis, 359
  - symptoms, 359
  - treatment, 359-360
- Growth hormone, 531
  - during pregnancy, 535-536
  - effect on lactation, 602
- Hemorrhage**, and shock in preoperative course, 636-637
- Hemorrhoids of urethra, 366
- Homograft, placenta as, 263-269
- Hormone(s)
  - adrenocorticotrophic (ACTH), 526, 531
    - increase in pregnancy, 533-535
  - adrenal cortical, 526-527, 531, 542-545
    - glucocorticoids, 543-544
      - See also Cortisol; Cortisone
    - mineralocorticoids, 544-545
      - See also Aldosterone
    - sex steroids, 527, 545
  - anterior pituitary, 522, 531-536
    - feedback effect, 531
    - See Gonadotropins; Growth hormone
  - antidiuretic (ADH), 529, 530-531
    - vasopressor effect, 531
  - estrogen. See Estrogen(s); Estriol
  - gonadotropic. See Gonadotropin(s)
  - luteotropic (LTH), 531
    - in pregnancy, 535-536
  - ovarian, 522, 523-525
    - See Estriol; Estrogen(s); Progesterone; Relaxin
  - parathyroid, 546-547
  - placental, 541-542
  - producing glands, 528
  - thyroid, 527, 531
    - during pregnancy, 536, 545-546
- Hurler's syndrome, 337
- Hydatidiform mole, estriol levels in, 560
- Hydronephrosis, 386
- Hydroureter, 386
- Hyperchloremic acidosis, 733
- Hyperthyroidism
  - maternal, 77
  - menstruation, as affected by, 79
- Hypophysectomy, and effect on sperm motility, 125
- Hypospadias, 356-357
- Hypothalamus
  - and pregnancy, 528-529
  - relationship to pituitary, 528
  - role of, in gonadotropic secretion, 522
- Hypothyroidism
  - menstruation, as affected by, 79
  - treatment of maternal, 78
- Hysterectomy
  - for cervical cancer, 393, 616
  - carcinoma in situ following, 760
  - complications following, 393-394, 700-701, 774-782
    - gastrointestinal, 780
    - lymphocysts, 779-780
    - thromboembolic disease, 780, 782
    - urinary tract, 775-779
  - extensive abdominal and pelvic lymphadenectomy, 659-675
    - blood loss during, 661, 667, 668, 671
    - surgical technique, 660-675
  - radical vaginal (Schauta-Amreich operation), 676-703
    - complications, 700-701
    - end results, 701, 702, 703
    - indications for, 677-678
    - postoperative mortality, 701
    - postoperative treatment, 699-700
    - preoperative investigation, 678
    - preoperative radium treatment, 677
    - preparation of patient, 678
    - surgical technique, 678-699
  - subtotal, 383
  - supracervical, 384
  - total abdominal
    - for benign disease, 376-382, 383-384
    - technique, 379-381
    - ureteral injury, 383-384
    - for cancer of endometrium, 623-624
  - total vaginal, for benign disease, 383

- Hysteria, 163-164, 239-242  
 clinical management of hysterical  
   breakdown, 241-242  
 clinical picture, 240-241  
 and hysterical personality, 163-164
- Hysterosalpingography, 35-41  
 interpretation of films, 37-41  
 pregnancy after, incidence of, 40-41  
 radiation, effect on ovaries, 39-40  
 technique, 36-37, 38, 39
- I**mmunologic paralysis, 272
- Infection  
 of periurethral glands, 362-363  
 following radical surgery, 637  
 urethral, 359-363
- Infertility  
 adrenal glands, effect on, 81-87  
   tests, clinical, of dysfunction, 83-86  
 anterior pituitary gland, effect on, 73-77  
   acromegaly, 74  
   Chiari-Frommel syndrome, 74, 75-77  
   gonadotropins, deficiency of, 74, 75  
   "hypothalamic amenorrhea," 77  
   panhypopituitarism, 74  
 cervical factor in, 15-29  
   *See also* Cervix  
   investigation of, 19-25  
   characteristics of mucus, 16-19  
   related conditions, 20-21  
     chronic cervicitis, 21, 23  
     electrocauterization, 20, 21, 23  
     estrogen deficiency, 21  
     lesions, cervical, 21, 26-27  
     retrodisplacement, 20, 26  
     uterus, prolapse of, 20, 26  
     vaginal, 20, 26  
   tests for determination of, 23-25  
   treatment of, 26-31  
 coitus, poor techniques of, 103-104  
 improvement of, 26  
   dietary factors, effect of, 103  
 emotional aspects of, 100-114  
   diagnosis, methods of, 104-113  
     psychometric testing, 108-113  
     tests, 106. *See also* Postcoital test;  
     Tubes, fallopian, insufflation  
   psychogenic factors, 102-103  
   treatment of, 113  
 endometriosis in, 55-56, 66-67  
   *See also* Endometriosis  
 immunologic causes of, 25-26, 93-96  
 ABO blood incompatibility, 93-94  
 sperm-agglutinating antibodies, 95  
 autoimmunity, 94-95  
   *See also* Contraception, immuno-  
     logic aspects  
 male, 128-131  
   history, 128, 132-133  
   physical examination, 128-129  
     cryptorchism, 130  
     surgical treatment of, 139-140  
   endocrine disturbances, 130  
   genetic disturbances, 130  
   mumps orchitis, 130  
 semen examination. *See* Semen ex-  
   amination  
   sperm ducts, blocked, 130  
     surgical treatment of, 139  
   varicocele, 130  
     surgical treatment of, 138  
   vas deferens, congenital absence  
     of, 130  
 treatment of, 132-140  
   medical, 133-138  
     endocrine methods, 135-138  
     insemination, artificial, 135  
     *See also* Artificial insemina-  
       tion  
     nutritional measures, 133  
     semen, cultures of, 134  
     sperm, storing and concentra-  
       tion of, 134-135  
     psychologic measures, 133  
     surgical, 138-140  
   metabolic factors, 103  
 myomas, uterine, effect on, 52  
 ovarian factor in, 58-71  
   *See also* Ovary  
 spermatogenesis, failure of, 103  
   *See also* Infertility, male  
 thyroid function and, 77-81, 103  
   miscarriages, incidence of, 77  
 unexplained, 93-96
- J**aundice  
 and remission of rheumatoid arthritis,  
   293-294
- Johnson Temperament Analysis, 108-113
- L**actation  
 anterior pituitary factors, 602  
 effect of oxytocin on, 529  
 galactopoiesis, 601, 604-605



- lactogenesis, 601-603  
 milk ejection reflex, 529, 601, 603  
 ovarian hormones in, 601-602  
 sucking reflex, 603-604  
 suppression of, 517, 605-606  
 theories of mechanism, 602-603  
 Lymphocysts following radical pelvic surgery, 779-780
- Marfan syndrome, 336-342**  
 basic defect, 338-339  
   chromosomal abnormality, 339  
   elastic-fiber defect, 338  
   metabolic defect, 339, 342  
 clinical picture in, 339-340  
 diagnosis, 342  
   dissecting aortic aneurysm, 342-346  
     animal studies, 344  
     case studies, 345-346  
     effect on blood vessels, 344  
     intramural hematoma, 343  
     period of gestation and, 343  
     preceded by degeneration of aortic media, 343  
     stress of labor, 345  
 heredity, 338  
 incidence, 338  
 laboratory findings, 340-342  
   acid mucopolysaccharide levels, 341  
   aortic aberrations, 342  
     aortography and angiocardiography, 341  
     excretion of hydroxyproline, 340-341  
 and pregnancy, 342-347  
 skeletal manifestations of, 336-338  
 treatment, 342
- Membrane rupture  
 premature, and estriol excretion, 552-554
- Menouria, 478
- Menstruation  
 contemporary beliefs, 226-231  
   maternal attitude, effect on child, 227-230  
   historical beliefs, 223-226  
   hyperthyroidism, effect of, on, 79  
   hypothyroidism, effect of, on, 79  
 Milk ejection reflex, 529, 601, 603  
 Müllerian duct, embryology of, 48, 49  
 Myomas of uterus, 52-55  
   *See also* Uterus, myomas of
- Nephrectomy, 429-432, 433, 449, 451-452**
- Nephrostomy, 432**
- Neurohypophysis. *See* Pituitary, posterior
- Newborn, effect of scleroderma on, 284
- Oligospermia**  
 consistent, 123  
 definition of, 118  
 and hypermotility, 130
- Osteogenesis imperfecta, 337
- Ovary  
 adrenal and thyroid glands, effect on, 60  
 biochemistry of ovarian secretion, 59  
 cyclic changes in, 58-59  
 disorders of, nonendocrine, 66-68  
 endometriosis, 66-67. *See also* Endometriosis  
   inflammation, 67-68  
     gastrointestinal, and ovary, 67  
   ovarian abscess, 66-67  
   periophoritis, 68  
 neoplasms, 68  
 hormone secretion. *See* Hormones, ovarian  
 inadequate luteal phase, 68-71  
 regulation of, 59-60  
 Stein-Leventhal syndrome, 62-66  
 clinical pattern and diagnosis of, 62-63, 64  
 laboratory findings, typical, 63  
 pathogenesis of, 63-65  
 treatment of, 65-66
- Ovulation temperature graph, 113
- Oxytocin, 528  
 chemistry of, 529  
 and milk ejection reflex, 529, 604  
 during pregnancy, 529-530  
 in puerperium, 530  
 uterine effect of, 529-530
- Oxytocinase, 530
- Pain**  
 Gestalt pain, 162  
 pathogenesis of, 161-162  
   levels of biologic pain-symbolization, 162  
   "pain spectrum," 162  
   *See also* Pelvic pain
- Pancreas  
 effect of pregnancy on, 518, 547
- Papanicolaou staining technique, use of in seminal cytology, 119
- Pelvic congestion syndrome, 164-165

- Pelvic pain  
 psychogenic, **161-172**  
   clinical findings, 168  
   diagnosis, 167-168  
     differential diagnosis, 168-170  
     hypno- and narcoanalysis in, 167-168  
   hysteria and hysterical personality, 162-164  
   pathology, **164-168**  
     pelvic congestion syndrome, 164-165  
   prognosis, 172  
   prophylaxis, 172  
   treatment of, 169, 171
- Pituitary  
 anterior  
   during pregnancy, **531-536**  
   hormones of, **531-536**  
   relationship to hypothalamus, 528  
 posterior  
   and ADH production, 530-531  
   function of, 529  
   and oxytocin production, 529-530  
     *See also* Oxytocin  
   during pregnancy, 529-531
- Placebos, **206-209**  
   in pelvic pain, 171  
   side effects of, 208-209  
   in stressful situation, 208  
   toxic reaction to, 208
- Placenta  
   endocrine activities of, **580-597**  
     methods of investigation, **581-586**  
   enzymes of, 574  
   estriol secretion and placental insufficiency, 560  
   as a homograft, **263-269**  
     hypotheses for, **263-266**  
       immunologically immature fetus, 263-264, 277  
       physiologic barrier between mother and fetus, 263, 264-265, 277  
       uterus as a privileged site, 263, 264, 277  
       weakened immunologic reactivity of mother, 263, 266, 277  
   perfusion in situ, 585  
   perfusion in vitro, 584-585  
     protein hormone secretion, **586-589**  
     progesterone levels, 570-574  
       during labor, 571, 572  
       in early pregnancy, 571  
       postpartum, 572, 573  
       prior to labor, 571  
       and vasopressinase production, 531
- Polyarteritis nodosa  
   classification of, 323  
   diagnosis, 329-330  
   etiology of, 322  
   initial morphologic changes, 322  
   and pregnancy, **324-332**  
     effect on disease, 326-327  
     effect of delivery on, 331  
     fetal outcome, 328-329  
     historical review, 324-327  
     maternal outcome, **324-328**  
     treatment of, 330-332  
       with cortisone, 330  
       effect on fetus, 331  
   remission of, 330  
   symptoms, 323-324, 329
- Polycystic ovary syndrome. *See* Stein-Leventhal syndrome
- Postcoital test (Sims-Hühner)  
   "immediate," 25  
   results, classification of, 24-25, 106, 122  
   time of, 24, 25
- Pregnancy  
   adolescent response to, 149-150  
   collagen diseases in, 276-277  
   and dermatomyositis, 305-306  
   diabetes in, 547  
   endocrine function during, 267-269, **528-547**  
   immune mechanisms in, **263-278**, 271-272  
   and increase in protein-bound cortisol, 293  
   and Marfan syndrome, **342-347**  
   pigmentary changes in, 534-535  
   and polyarteritis nodosa, 324-332  
   progesterone needs in, **536-539**, 566  
   pyelonephritis in, 555-556  
   and rheumatoid arthritis, 276, 278, **286-301**  
   and scleroderma, **280-284**  
   steroid metabolism, 293  
   and SLE, 277, 288, **307-320**  
   tests for, 91  
     phenothiazine derivatives, effect of, on, 213  
     reactions in, 91, 92  
     tranquilizers, use of during, 217-218  
   thymolymphatic system in, 266, **269-272**

- thymus during, 267  
 thyroid changes, 545-546  
**Progesterone**  
   administration, 565  
   bioassay versus physicochemical data, 569-570  
   biologic activities of, 566  
   after delivery, 576  
   effects of, 525  
   fetal influences on metabolism of, 539, 574-577  
   guides to usage, 567-568  
   measurement, 525  
   during pregnancy, 536-539, 565-578  
   levels of 6-oxygenated compounds, 575-576  
   secretion of, 568  
   source of, 568-569  
   synthetic agents, 567  
   in combination with estrogens, 567  
   validity of studies on secretion of, 576-577  
**PSP test**, 419  
**Pseudo-xanthoma elasticum**, 337  
**Pyelonephritis**  
   in pregnancy, 555-556  
   maternal urinary estriol level, 556  
**Raynaud's phenomenon** and dermato-  
   myositis, 304  
**Relaxin**, 541-542  
**Rheumatoid arthritis**, 274-275, 286-287  
   age incidence, 290  
   anemia in, 288  
   and delivery, 295  
   diagnosis of, 288-289  
   hereditary factors, 290-291  
   and lupus erythematosus, 275, 288  
   as manifestation of autoimmunity, 274-  
     275, 277-278, 294  
   onset, 290  
   and pregnancy, 276, 291-295  
     amelioration of activity, 291-292,  
       330  
     mechanisms of effect, 292-295  
       changes in steroid metabolism,  
       293, 330  
       increase in protein-bound cor-  
       tisol, 293  
       spontaneous jaundice, 293-294  
     onset, 291  
     exacerbation of symptoms, 291-292  
     relapse of disease following delivery,  
       291  
     prognosis of, 289-290  
     and renal disease, 287-288  
     rheumatoid factor, 289  
       transmission from mother to fetus,  
       295  
   rheumatoid nodule, 287  
   sex incidence, 290  
   treatment of, 294, 295-300  
     analgesic therapy, 296  
     bed rest, 295-296  
     blood transfusions, 294  
     chloroquine, 297  
     cortisol (Compound E), 298-300  
     estrogens, 294  
     gold, 297-298  
     indomethacin, 299-300  
     phenylbutazone, 299  
     progesterone, 294  
     salicylates, 296-297, 300  
     splinting of inflamed joints, 296  
   and rheumatoid arthritis, 275  
   serum LE factor, 275, 329  
   time of onset, 308  
**Rheumatoid factor**, 289  
**Rubin test**. *See* Tubes, fallopian, insuffla-  
   tion  
**Schauta-Amreich operation**. *See*  
   Hysterectomy, radical vaginal  
**Scleroderma**  
   age incidence, 280  
   diagnosis of, 280-281  
   and newborn, 284  
   and pregnancy, 280-284  
     cardiovascular effects, 282  
     delivery, 283-284  
     gastrointestinal problems, 281-282  
     kidney effects, 282  
     nutritional problems, 282  
     skin effects, 281  
   prognosis for, 281  
   therapy of, 282-283  
     and toxic effect, 282, 283  
**Semen examination**, 115-126, 129-130  
   cytology, seminal, 118-121  
     aspermia, 121  
     miscarriage, repeated, and, 129-130  
     pus cells, 134  
     spermatozoal structure, 119-121,  
       129-130  
     and varicocele, 123  
   ejaculate volume, 121-122, 129  
   specimen, obtaining of, 115-116  
   sperm count, 118, 123, 129, 130  
   sperm motility, 116-118, 123, 124, 129

- continence, prolonged, effect on, 117-118, 125  
 hypophysectomy, effect on, 125  
 improvement of, by use of exogenous testosterone, 124-125  
 initial examination for, 116  
 and viscosity, high, 122-123  
 viscosity and agglutination, 122-123, 129  
 delayed liquefaction, 122  
 Sexual adjustment following radical pelvic surgery, 640-641  
 Shock  
   in postoperative course, 636  
   associated with infection, 637  
   associated with hemorrhage, 636-637  
 Sling operation for restoration of urinary continence, **461-464**  
 Somatotrophic hormone (STH). *See* Growth hormone  
 Spinnbarkeit, 16, 17, 22, 23  
   *See also* Cervix, mucus  
 Stein-Leventhal syndrome, **62-66**  
   *See also* Ovary, Stein-Leventhal syndrome  
 Steroid(s)  
   administration of, in placental studies, 582-583, 584, 586  
   17-ketosteroids, 527  
   *See also* individual steroid hormones  
 Stress syndromes in gynecology, **233-243**  
   depression, **236-239**  
     Beck Inventory for measuring, 238  
     clinical management, 238-239  
     antidepressant drugs, use of, 239  
     clinical picture of, 236-238  
     laboratory tests, 237  
     physical examination, 237  
     symptoms, 237  
   hysteria, **239-242**. *See also* Hysteria  
   schizophrenia, 242-243  
   tension, 234-236. *See also* Tension  
 Sucking reflex, 603-604  
 Surgery  
   pelvic  
     complications of, **771-785**  
     indications for, 611-612, 629, 706  
     methods of urinary diversion in, **726-755**  
     operative care, 633-635  
     postoperative care, 635-636  
     postoperative complications and treatment, **636-641**  
     preoperative care, **629-633**  
   total evisceration, **705-723**  
     complications of, **782-785**  
     indications for, 706  
     contraindications to, 706-707, 723  
     operative procedure, **707-722**  
       closure of pelvic peritoneum, 721-722  
       deep pelvic dissection, 715, 718  
       pelvic lymphadenectomy, 718-721  
       urinary diversion, **711-715**  
 Syphilis, 360-361  
   chance of, 360  
   differential diagnosis, 360  
   secondary, 361  
   treatment of, 361  
 Systemic lupus erythematosus (SLE), 275-276  
   and abortion, 277  
   diagnostic criteria, 307-308  
   postpartum activity of disease, 309  
   and nephritis, 277  
   and pregnancy, 277, 278, **307-320**  
     activity of disease, 308, 309, 310, 311-312, 314  
     exacerbation of, 309, 310-312  
     mild, 308  
     moderately active, 308  
     remission of, 309  
     severe, 308  
   adrenal cortical steroids, 319  
   age of onset, 308  
   effects of disease on conception, 312  
   effects of disease on outcome, **312-319**  
     duration of disease, 318-319  
     manifestations of disease, **314-318**  
     pattern of disease in multiple, 312  
   and prematurity, 277  
 Tension  
   clinical management of, 235-236  
   clinical picture of, 234-235  
   psychological factors in, **222-232**  
   therapy for, 231  
   premenstrual, 235  
   symptomatic illness, 235  
 Thromboembolic disease, following radical pelvic surgery, 780, 782  
 Thymolymphatic system  
   factors affecting function of, 266  
   in normal pregnancy, 266, **269-272**  
   animal studies, 269-270  
 Thyroid gland  
   effect of pregnancy on, 545-546

- function in nonpregnant female, 527  
tests for, 527
- Tissue, connective  
composition of, 334-336  
heritable disorders of, 336, 337  
See also Marfan syndrome
- Toxemia of pregnancy  
differentiated from periarteritis nodosa, 330  
maternal estriol levels in, 554-555
- Tranquilizers  
classification of, 209-216  
non-phenothiazine drugs, 213-216  
diphenylmethanes, 214  
miscellaneous, 214, 216  
propanediols substituted, 214  
*Rauwolfia* alkaloids, 213-214  
phenothiazine derivatives, 209-213  
aliphatics (dimethylamines), 209, 210  
piperazine (piperaziny), 209, 210  
piperidine (piperidyls), 209, 210  
side effects of, 210-213  
combined-drug therapy, 218-219  
non-drug factors, role of, 199-209  
clinician and nursing team, 203-204  
interaction between patient and, 204-205  
environment, physical, 204  
patient, 200-203  
perception of drug by, 205-206  
psychologic structure of, 206  
placebo studies, 206-209  
side effects of administration, 208-209  
social setting, 204  
use of, in gynecology, 197-220  
evaluation of, 199  
in pregnant patient, 217-218  
in psychotic patient, 218  
selection of, 198-199  
in serious physical pathology, 216-217
- Trophoblast, 266  
chorionic, 532-533
- Tubes, fallopian, 32-46  
hysterosalpingography, 35-41. See also Hysterosalpingography  
insufflation, 32-35, 106  
contraindications for, 32-33  
duration of, 34  
in patency test, 33-35  
pregnancy after, incidence of, 35  
technique for, 33-35  
occlusions, types of, 42-45  
surgery on, 41-46  
postoperative care, 45-46  
prerequisites for, 41-42  
technique of, 43-46  
timing of, 42
- Tumors  
benign urethral, 363-364  
malignant urethral, 364-366  
radiosensitivity of, 619-621  
radiation response, 620  
sensitization response, 619-620
- Twins, high oxytocinase levels and incidence of, 530
- Ureterosigmoidostomy, 434, 730, 733  
hyperchloremic acidosis incident to, 733-734  
operative technique, 736-737
- Ureters  
anatomy of, 400, 401  
deliberate section of, 407-411, 432  
double, 386-387  
fistula of. See Fistula  
injury to  
bilateral, 384  
management during gynecologic surgery, 399-411  
prophylaxis, 402  
surgical treatment, 403-411  
management following gynecologic surgery, 413-452  
catheterization for, 417  
cystoscopy for, 417  
diagnosis, 415-417  
operations associated with, 401, 736-737  
pathologic conditions associated with, 401-402  
preoperative precautions, 399  
prevention of, in gynecologic surgery, 383-397  
following radiation therapy, 393-394  
recognition of, 402-403, 413-452  
review of literature, 384  
surgical trauma, 387-391  
types of, 385-387  
physiology of, 400-401  
obstruction, 413-414  
bilateral, 414, 440  
unilateral, 413-414, 440  
management of, 440-452  
typical features of, 289
- Ureterostomy  
cutaneous, 726-730  
clinical examination, 726-727

- operative technique, **727-730**
  - bilateral side-by-side, 729-730
  - flank, 728-729
- Urethra
  - adenomas of, 363
  - anatomy of, 355-356
  - anomalies of, 356-358
    - abnormal opening of ureter into urethra, 356
  - absence of urethra, 356, 454-455
  - congenital urethral strictures, 357-358
  - duplication of, 356
  - epispadias, 357, 454
  - hypospadias, 356-357
  - benign papillomas of, 363
  - caruncle of, 363-364, 367
  - diverticulum of, **369-375**
    - acquired, 369, 374
    - congenital, 369
    - diagnosis, 370-372
    - medical treatment, 372
    - recurrence of, 374
    - surgical treatment, 372-375
    - symptoms of, 369-370
  - eversion and prolapse, 367
  - hemorrhoids of, 366
  - infections of, **359-363**
    - gonorrhea, 359-360
    - periurethral abscess, 362-363
    - postinfectious strictures, 367-368
    - syphilis, 360-361
    - trichomonal, 361-362
  - malignant melanoma of, 364
  - malignant tumors of, 364-366
  - polyps of, 363
  - primary carcinoma of, 365-366
  - reconstruction of, **454-464**
    - by flap of vaginal mucosa, **455-458**
    - followed by sling operation, **461-464**
    - by mucosa of the urethral region, 458-460
  - sarcoma of, 364-365
  - strictures of, 367-368
  - stripping of, 370, 371
  - suburethral cyst, 366-367
  - thrombosed veins, 366
  - traumatic injury to, 358-359, 454
  - venereal warts, 363
- Urethrograms, 372
- Urethroscopy, 370, 371, 372
- Urinary diversion, 432, 434, **711-715**, **726-755**
  - by cutaneous ureterostomy, 432, 434, **726-730**
  - by ureterointestinal anastomosis, 730, **733-754**
- Urinary incontinence
  - dribbling, 369
  - stress, 369, 374
  - sling operation for, 461
- Urinary tract
  - malformations of, 386-387
- Uterus
  - developmental anomalies of, **48-52**
    - and abortion, incidence of, 50
    - prevention of, regimen for, 50, 52
  - embryology of, 48
  - endometriosis, 55-56
    - See also Endometriosis
  - malposition of, 56-57
  - myomas of, 52-55
    - and fertility, effect on, 52
    - and miscarriages, incidence of, 52
  - myomectomy, 53-55
    - indications for, 53-54
    - pregnancy after, incidence of, 53-54
    - technique of, 54-55
  - oxytocin, effect on, 529-530
- Vagina
  - cancer of, 614-616
  - lymphatics of, 614-615
- Vulva
  - cancer of, 612-614
  - surgical treatment of, 612-613
- Vulvectomy
  - radical, **642-658**
    - anesthesia for, 643
    - complications of, **771-785**
      - lymphedema following, 656-657
      - marginal necrosis of skin flaps following, 656
      - slough of skin, 772-773
      - vascular, 773-774
    - end results, 657-658
    - operative technique, **643-654**
      - dissection of groin, 645-647, 648
      - final phase, **651-654**, 655
      - lymph node dissections, **647-650**
      - site of transverse incision, 643-644
      - closing of, 651, 652
    - postoperative management, 654, 656-657
      - antibiotic therapy, 654, 656
    - preoperative management, 642-643
- Wertheim operation, 609
  - for treatment of cervical cancer, 616

